ALS study seeks to match drug to patient type

This study looks at how the FDA-approved drug edaravone (Radicava) affects people with different forms of ALS. Researchers will collect blood, urine, and spinal fluid samples from 160 participants to measure markers of oxidative stress. The goal is to identify which ALS patients benefit most and how long treatment should last. No new medication is given; edaravone is prescribed as part of regular care.